CORV - Correvio Pharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9700
-0.0700 (-3.43%)
As of 3:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.0400
Open2.0300
Bid1.9600 x 900
Ask1.9900 x 800
Day's Range1.9200 - 2.0300
52 Week Range1.9200 - 5.2400
Volume206,267
Avg. Volume93,704
Market Cap73.234M
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.4730
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.44
Trade prices are not sourced from all markets
  • Hedge Funds Have Never Been This Bullish On Correvio Pharma Corp. (CORV)
    Insider Monkey18 days ago

    Hedge Funds Have Never Been This Bullish On Correvio Pharma Corp. (CORV)

    Is Correvio Pharma Corp. (NASDAQ:CORV) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk […]

  • CNW Group23 days ago

    Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation

    VANCOUVER , June 24, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Brinavess™ (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF). "The resubmission of the Brinavess NDA is a major milestone for Correvio and is the culmination of substantial effort by our employees and the investigators who have dedicated themselves toward investigating this potential new treatment option for adult patients with recent onset AF," said Mark H.N. Corrigan , MD, CEO of Correvio.

  • CNW Group29 days ago

    Correvio Announces Voting Results

    Correvio Announces Voting Results

  • Associated Press2 months ago

    Correvio: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 23 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...

  • CNW Group2 months ago

    Correvio Reports First Quarter 2019 Financial Results

    Correvio Reports First Quarter 2019 Financial Results

  • PR Newswire3 months ago

    Correvio to Report First Quarter 2019 Financial Results on May 8, 2019

    Conference Call Scheduled for Wednesday, May 8, 2019 at 8:30 a.m. Eastern ( 5:30 a.m. Pacific) NASDAQ: CORV  TSX: CORV VANCOUVER , May 1, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: ...

  • ACCESSWIRE3 months ago

    Cannabis Industry Consuming Energy at An Alarming Rate: Investing in Solutions

    HENDERSON, NV / ACCESSWIRE / April 9, 2019 / As per the report, "The Cannabis Energy Report: Current and Evolving State of Cannabis Energy Consumption" published by New Frontier Data, cannabis ...

  • PR Newswire3 months ago

    Correvio Announces Zevtera® Abstracts at ECCMID 2019

    NASDAQ: CORV   TSX: CORV Seven Data Abstracts Selected for Poster Presentations   VANCOUVER , April 3, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company ...

  • CNW Group3 months ago

    Correvio Announces Xydalba™ (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019

    Correvio Announces Xydalba™ (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019

  • CNW Group3 months ago

    Correvio to present at the H.C. Wainwright Global Life Sciences Conference

    Correvio to present at the H.C. Wainwright Global Life Sciences Conference

  • PR Newswire4 months ago

    Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting

    VANCOUVER, March 20, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of new Brinavess® (vernakalant hydrochloride, IV) data at the American College of Cardiology 2019 Annual Meeting taking place March 16-18, 2019, in New Orleans.  This poster presentation highlights reduced hospitalization in patients treated with Brinavess, Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF at the Hillel Yaffe Medical Center located in Hadera, Israel. This presentation, titled "Intravenous Vernakalant for the Treatment of New-Onset Atrial Fibrillation in the Emergency Department," was given by Jameel Mohsen, MD, Hillel Yaffe Medical Center.

  • PR Newswire4 months ago

    Correvio Announces at the Market Offering

    VANCOUVER, March 14, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), ("Correvio" or the "Company"), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has entered into an At the Market Sales Issuance Agreement dated March 13, 2019 (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor") as agent, pursuant to which the Company may, from time to time sell, through "at-the-market" offerings on the Nasdaq Capital Market  or another existing trading market in the United States with Cantor as agent, such number of common shares as would have an aggregate offer price of up to US$50,000,000 subject to a limit of US$12,000,000 under the ATM Prospectus Supplement (as defined below). Cantor, at Correvio's discretion and instruction, will use its commercially reasonable efforts to sell the common shares at market prices from time to time.

  • CNW Group4 months ago

    Correvio Reports Fourth Quarter and Full Year 2018 Financial Results

    Correvio Reports Fourth Quarter and Full Year 2018 Financial Results

  • CNW Group4 months ago

    Correvio Announces Amendment To Term Loan With CRG-Managed Funds

    VANCOUVER , March 11, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced an amendment to its existing agreement with CRG Servicing LLC ("CRG") dated May 11, 2017 (the "Amending Agreement"), which provides for an increase in capital available to the Company.  Under the terms of the amended agreement, Correvio is now eligible to receive up to an additional $10 million .  Under the Amending Agreement, Correvio will pay a small access fee to CRG.  The additional funding may be drawn at Correvio's discretion in increments of $2.5 million through September 30, 2019 and there will be prepayment premium associated with any such draw-down. "This amended credit facility provides important non-dilutive, near-term capital as well as greater financial flexibility to achieve our corporate objectives this year," said William Hunter , MD, CEO of Correvio.  "Based on our current operating plan, the net proceeds from CRG, combined with our existing cash, provide us with enough capital to get an answer from the U.S. Food and Drug Administration on the Brinavess® New Drug Application which we remain on track to resubmit the Brinavess NDA during the second quarter of 2019.